Adriaan J. van der Meer

Dr. Adriaan J. van der Meer

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
MHMaren H. Harms
Maren H. Harms
HBHenk R. van Buuren
Henk R. van Buuren
CCChristophe Corpechot
Christophe Corpechot
DTDouglas Thorburn
Douglas Thorburn
HJHarry L.A. Janssen
Harry L.A. Janssen
Adriaan J. van der MeerAdriaan J. van der Meer
Adriaan J. van der Meer

1 March 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
Adriaan J. van der MeerAdriaan J. van der Meer
Adriaan J. van der Meer
JFJordan J. Feld
Jordan J. Feld
HHHarald Hofer
Harald Hofer
PAPiero L. Almasio
Piero L. Almasio
VCVincenza Calvaruso
Vincenza Calvaruso
HJHarry L.A. Janssen
Harry L.A. Janssen

1 October 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
Adriaan J. van der MeerAdriaan J. van der Meer
Adriaan J. van der Meer
MBMarina Berenguer
Marina Berenguer

1 May 2021 in Journal of Hepatology
Verified
Journal Article
Open access
LKLisette A.P. Krassenburg
Lisette A.P. Krassenburg
RMRaoel Maan
Raoel Maan
ARAlnoor Ramji
Alnoor Ramji
MMMichael Manns
Michael Manns
MCMarkus Cornberg
Markus Cornberg
Adriaan J. van der MeerAdriaan J. van der Meer
Adriaan J. van der Meer
HCV-infected patients with cirrhosis achieve high sustained virological response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic decompensation. We aimed to assess the clinical outcome following DAAs among patients with compensated and decompensated cirrhosis in relation to SVR and changes in model for end-stage liver disease (MELD) score. Consecutive DAA-treated chronic HCV-infected patients with cirrhosis from 4 hepatology clinics were included. The primary endpoint in survival analyses was clinical disease progression, defined as liver failure, hepatocellular carcinoma, liver transplantation or death. In total, 868 patients were included with a median age of 59 (IQR 54-65) years; 719 (83%) with Child-Pugh A cirrhosis and 149 (17%) with Child-Pugh B/C cirrhosis. SVR was attained by 647 (90%) Child-Pugh A patients and 120 (81%) Child-Pugh B/C patients. During a median follow-up of 28 (IQR 20-36) months, 102 (14%) Child-Pugh A patients and 96 (64%) Child-Pugh B/C patients experienced clinical disease progression. SVR was independently associated with an improved event-free survival in patients with Child-Pugh A cirrhosis (adjusted hazard ratio [HR] 0.47; 95% CI 0.27-0.82, p = 0.007), but not in patients with Child-Pugh B/C cirrhosis (adjusted HR 1.23; 95% CI 0.67-2.26; p = 0.51). Twelve weeks post-DAAs, 28 (19%) patients with Child-Pugh B/C cirrhosis had ≥2-point MELD decline, but their 2-year event-free survival did not differ from those with a stable MELD (47.9%; 95% CI 28.7-67.1 vs. 48.9%; 95% CI 38.1-59.7, respectively, p = 0.99). Among patients with chronic HCV infection, DAA-induced SVR was associated with a reduced risk of clinical disease progression in patients with Child-Pugh A cirrhosis but not in patients with Child-Pugh B/C cirrhosis. In Child-Pugh B/C cirrhosis, a ≥2-point MELD decline did not translate into improved clinical outcome. Chronic HCV infection can be cured with antiviral therapy. In this study, we evaluated the long-term effects of antiviral therapy on liver-related complications in patients with cirrhosis. Our results suggest that patients with compensated cirrhosis who were cured of their HCV infection have a lower rate of complications. In contrast, the rate of complications was not related to virological cure among those with decompensated cirrhosis. While these patients seem to remain in need of liver transplantation, antiviral therapy may lower their priority on the liver transplantation waiting list.

28 June 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
CCChristophe Corpechot
Christophe Corpechot
FCFabrice Carrat
Fabrice Carrat
FGFarid Gaouar
Farid Gaouar
FCFrederic Chau
Frederic Chau
GHGideon Hirschfield
Gideon Hirschfield
VLVictor de Lédinghen
Victor de Lédinghen

13 December 2023 in Journal of Hepatology
Verified
Journal Article
Open access
RSRomée J.A.L.M. Snijders
Romée J.A.L.M. Snijders
ASAnna E.C. Stoelinga
Anna E.C. Stoelinga
TGTom J.G. Gevers
Tom J.G. Gevers
SPSimon Pape
Simon Pape
MBMaaike Biewenga
Maaike Biewenga
JDJoost P.H. Drenth
Joost P.H. Drenth
Patients with autoimmune hepatitis (AIH) almost inevitably require lifelong immunosuppressive treatment. There is genuine concern about the efficacy and tolerability of the current standard combination therapy of prednisolone and azathioprine. Mycophenolate mofetil (MMF) has emerged as an alternative option. The aim of this study was to compare MMF to azathioprine as induction therapy. In this 24-week, prospective, randomised, open-label, multicentre superiority trial, 70 patients with treatment-naive AIH received either MMF or azathioprine, both in combination with prednisolone. The primary endpoint was biochemical remission defined as normalisation of serum levels of alanine aminotransferase and immunoglobulin G after 24 weeks of treatment. Secondary endpoints included safety and tolerability. Seventy patients (mean 57.9 years (standard deviation (SD) 14.0); 72.9% female) were randomly assigned to the MMF plus prednisolone (n=39) or azathioprine plus prednisolone (n=31) group. The primary endpoint was met in 56.4% and 29.0% of patients assigned to the MMF group and the azathioprine group, respectively (difference, 27.4 percentage points; 95% confidence interval (CI), 4.0 to 46.7; p=0.022). The MMF group exhibited higher complete biochemical response rates at 6 months (72.2% vs. 32.3%; p=0.004). No serious adverse events occurred in patients who received MMF (0%) but serious adverse events were reported in four patients who received azathioprine (12.9%) (p=0.034). Two patients in the MMF group (5.1%) and eight patients in the azathioprine group (25.8%) discontinued treatment owing to adverse events or serious adverse events (p=0.018). In patients with treatment-naive AIH, MMF with prednisolone achieved a significantly higher rate of biochemical remission at 24 weeks compared to azathioprine combined with prednisolone. Azathioprine use was associated with more (serious) adverse events leading to cessation of treatment, suggesting superior tolerability of MMF. This randomised controlled trial directly compares azathioprine and mycophenolate mofetil (MMF), both in combination with prednisolone, for the induction of biochemical remission in treatment-naive patients with autoimmune hepatitis (AIH). Achieving complete remission is desirable to prevent disease progression. Patients assigned to the MMF group reached biochemical remission more often and experienced fewer adverse events. The findings in this trial may contribute to the re-evaluation of international guidelines for the standard of care in treatment-naive patients with AIH. #NCT02900443.